FOUZEE SugarLin HERBAL FORMULA capsules — Class I drug recall D-0207-2025
Ongoing recall by SHOPPERS- PLAZA, reported 2025-01-29, distributed nationwide. Marketed without an Approved NDA/ANDA; FDA laboratory analysis confirmed product tainted with undeclared metfo
| Recall number | D-0207-2025 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | SHOPPERS- PLAZA, Hawthorne, CA, United States |
| Recall initiated | 2024-12-16 |
| Classified | 2025-01-22 |
| Reported by FDA | 2025-01-29 |
| Distributed | Nationwide (US) |
| Reason classes | undeclared allergen, unapproved product |
| UPC / GTIN / UDI-DI | 00826656690477 |
| Lot numbers | 001 |
| Expiration dates | 2026-09-10 |
Product
FOUZEE SugarLin HERBAL FORMULA capsules, 180 capsules per bottle, Sold and Distributed by Shoppers-Plaza, Hawthorne, CA 90250. Product of India. UPC 8 26656 69047 7
Reason for recall
Marketed without an Approved NDA/ANDA; FDA laboratory analysis confirmed product tainted with undeclared metformin and glyburide
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0207-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.